Zero Basic Duty for 27 Medicines for Supply under Patient Assistance
Programmes
[Customs
Notification No. 16 dated 20th April 2017]
Seeks
to exempt goods falling under chapter 30 of first schedule of Customs tariff
Act 1975, for supply under Patient Assistance Programme run by specified
pharmaceutical companies.
In
exercise of the powers conferred by sub-section (1) of section 25 of the
Customs Act, 1962 (52 of 1962), the Central Government, being satisfied that it
is necessary in the public interest so to do, hereby exempts the goods, falling
under Chapter 30 of the First Schedule to the Customs Tariff Act, 1975 (51 of
1975), of the description specified in column (2) of the Table below, for
supply under Patient Assistance Programmes specified in the corresponding entry
in column (3) of the said Table, run by the pharmaceutical companies specified
in the corresponding entry in column (4) of the said Table, when imported into
India, from the whole of the duty of customs leviable
thereon which is specified in the First Schedule to the said Customs Tariff
Act, subject to the following conditions, namely:-
(a) the drugs and medicines are supplied free of cost to the
patients under the Patient Assistance Programme of the specified pharmaceutical
company;
(b) the said
pharmaceutical company furnishes an undertaking to the Assistant Commissioner
of Customs or the Deputy Commissioner of Customs, as the case may be, having
jurisdiction, to the effect that-
(i) it shall maintain the following records:-
(A) name, age,
gender, residence and contact details of the patient;
(B) copies of valid identity proof and residence proof of the
patient and the caregiver, if any, as the case may be;
(C) the disease diagnosed and the prescribed dosage of drugs and
medicines;
(D) the drugs and medicines imported or received and consumed
under the said programme;
(ii) the goods shall be used for the specified purpose only;
(c) The said
pharmaceutical company also furnishes an undertaking to the Assistant
Commissioner of Customs or Deputy Commissioner of Customs, as the case may be,
having jurisdiction, to pay, in the event of failure to comply with any of the
aforesaid conditions, an amount equal to the duty leviable
on such goods but for the exemption contained in this notification, along with
the applicable interest thereon.
|
Table |
|||
|
SNo. |
Description
of drug / medicine |
Name
of Patient Assistance Programme |
Name
of pharmaceutical company running Patient Assistance Programme |
|
(1)
|
(2)
|
(3)
|
(4)
|
|
1.
|
Xtandi
(Enzulatamide) |
Xtandi
Patient Assistance Programme |
Astellas
Pharma India Pvt. Ltd. |
|
2.
|
Dasatinib
(Sprycel) |
Sprycel
Assistance Program |
Bristol
Myers Squibb India Pvt. Ltd. |
|
3.
|
Nivolumab
(Opdyta) |
OASIS
|
Bristol
Myers Squibb India Pvt. Ltd. |
|
4.
|
Halaven
(Eribulin medylate) -
Metastatic Breast cancer, Soft Tissue Sarcoma |
Hope
to Her – 2 to 3 cycles purchased and balanced free upto
disease progression |
Eisai
Pharmaceuticals India Pvt. Ltd. |
|
HELP
- All cycles free for below poverty line patients |
Eisai
Pharmaceuticals India Pvt. Ltd. |
||
|
5.
|
Zonegran
(Zonisamide) - for Epilespy
|
Livefree
- 33% Support to patients for extending duration of treatment as this is a
chronic therapy |
Eisai
Pharmaceuticals India Pvt. Ltd. |
|
6.
|
Imbruvica
|
1+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
7.
|
Zytiga
|
3+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
8.
|
Velcade
1mg |
3+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
9.
|
Velcade
3.5 mg |
1+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
10.
|
Caelax
|
1+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
11.
|
Dacogen
|
1+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
12.
|
Yondelis
|
1+1
PAP |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
13.
|
Simponi
|
1
vial free on 1st purchase |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
14.
|
Remicade
|
5+4
on 3 dose therapy, 6+6 on 4 dose therapy |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
15.
|
Invega
all SKUs |
1+1
PAP (Maintenance dosage) |
Janssen
India, Johnson & Johnson Pvt. Ltd. |
|
16.
|
Imatinib
(Glivec) |
Glivec
NOA Program/ Glivec International PAP |
Novartis
India Ltd. |
|
17.
|
Nilotinib
(Tasigna) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
18.
|
Ruxolitinib
(Jakavi) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
19.
|
Everolimus
(Afinitor) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
20.
|
Ceritinib
(Spexib) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
21.
|
Pazopanib
(Votrient) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
22.
|
Eltrombopag
(Revolade) |
Win
for Patients - Cancer Care |
Novartis
India Ltd. |
|
23.
|
Indicaterol
(Sequadra) |
Win
for Patients - COPD |
Novartis
India Ltd. |
|
24.
|
Secukinumab
(Scapho) |
Win
for Patients - Skincare |
Novartis
India Ltd. |
|
25.
|
Omalizumab
(Xolair CSU) |
Win
for Patients – Skin care |
Novartis
India Ltd. |
|
26.
|
Ranibizumab
(Accentrix) |
Win
for Patients - Visioncare |
Novartis
India Ltd. |
|
27.
|
RITUXIMAB
|
SPARSH
- The Touch |
Dr.
Reddy's Laboratories Ltd. |
[F.No.332/24/2010-TRU
(Pt.I)]